Davunetide and the GSK-3 inhibitor tideglusib are currently in phase II clinical trial for the treatment of predicted tauopathies or AD and PSP, respectively (ClinicalTrial.gov identifier-davunetide = NCT01056965, tideglusib = NCT01049399 and NCT01350363), providing first clinical data about the efficiency of tau phosphorylation modulating drugs (Gozes 2010). This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.